These data are from a study of B16F10 melanoma tumors in nude mice, n=6 in each group. A single tail vein injection of 150μl of nanorod dispersion (~1.1mg/kg) was given 12-14 hours before a 6-minute treatment with 850nm infrared light at ~1W/cm2 flux. Siva completed rodent tumor efficacy studies, using a contract lab, and also through the Nanotechnology Characterization Laboratory (NCL, https://ncl.cancer.gov/) program, which is the world-leading national laboratory for cancer nanotherapies, funded by the National Cancer Institute and the FDA.
These data are from a collaborative study Siva performed with Plexxikon, the company that developed the BRAF inhibitor vemurafenib (Zelboraf.) Plexxikon had identified a tumor type with the V600E mutation that was largely resistant to vemurafenib, and they wanted to see if hyperthermia could complement drug activity. Hyperthermia at both 42°C and 44°C tumor temperature for 6 minutes was tested, with significantly better results at 44°C. Plexxikon provided the tumor model and vemurafenib rodent chow (“PLX4720”) they developed. The study was performed by preclinical CRO Bolder BioPATH.
Results of Siva-Plexxikon collaborative mouse study using a vemurafenib (Zelboraf) resistant tumor type and mono- or combination treatment with Siva’s Targeted Hyperthermia (44°C and 42°C) and Zelboraf. 44°C was significantly more effective than 42°C. Mice surviving at 95 days had no evidence of tumor histologically after sacrifice. Plexxikon provided the tumor model and vemurafenib rodent chow they developed. The study was performed by preclinical CRO Bolder BioPATH.